Amicus Therapeutics (FOLD) : 6 brokerage houses believe that Amicus Therapeutics (FOLD) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Amicus Therapeutics (FOLD). Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 7 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.29.
Amicus Therapeutics (FOLD) : The consensus price target for Amicus Therapeutics (FOLD) is $14 for the short term with a standard deviation of $3.83. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $19, however, the pessimist price target for the company is $9.
For the current week, the company shares have a recommendation consensus of Buy. Amicus Therapeutics (NASDAQ:FOLD): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.36 and $6.27 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.80. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.71, notching a gain of 6.85% for the day. The total traded volume was 2,338,546 . The stock had closed at $6.28 on the previous day.
In a related news, Barth Jay, officer (Chief Medical Officer) of Amicus Therapeutics Inc, unloaded 20,916 shares at an average price of $7 on July 27, 2016. The total amount of the transaction was worth $146,412, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.